

21 Apr 2024 | News

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: Teva's immunology biosimilar launches; Intra-Cellular's promising depression data; Phase III sleep apnea win for Lilly's tirzepatide; an interview with Viking's CEO; and China looks to define innovative drugs.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 19 April 2024, including: [Teva Pharmaceutical Industries Ltd.](#)'s immunology biosimilar launches; [Intra-Cellular Therapies, Inc.](#)'s promising depression data; Phase III sleep apnea win for [Eli Lilly and Company](#)'s tirzepatide; an interview with [Viking Therapeutics, Inc.](#)'s CEO; and China looks to define innovative drugs.

This and all our other podcasts are available on the *Citeline* channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches](#)" - Scrip, 17 Apr, 2024.)

(Also see "[First Phase III Depression Data For Intra-Cellular's Caplyta Exceed Expectations](#)" - Scrip, 16 Apr, 2024.)

(Also see "[Lilly Can Rest Easy As Tirzepatide Scores Phase III Sleep Apnea Win](#)" - Scrip, 17 Apr, 2024.)

(Also see "[*A Good Choice To Have: Scrip's Interview With Viking CEO Brian Lian*](#)" - Scrip, 12 Apr, 2024.)

(Also see "[*Explained: How China's Public Payer Wants To Define Innovative Drugs*](#)" - Scrip, 17 Apr, 2024.)

[*Click here to explore this interactive content online*](#) ✨